UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Nature reviews. Clinical oncology, 2019-09, Vol.16 (9), p.563-580

2019

Volltextzugriff (PDF)

Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma

Nature communications, 2024-04, Vol.15 (1), p.3664-3664, Article 3664

2024

Volltextzugriff (PDF)

Interactive process mining of cancer treatment sequences with melanoma real-world data

Frontiers in oncology, 2023-03, Vol.13, p.1043683-1043683

2023

Volltextzugriff (PDF)

Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events

Journal for immunotherapy of cancer, 2022-10, Vol.10 (10), p.e005635

2022

Volltextzugriff (PDF)

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

Journal for immunotherapy of cancer, 2021-02, Vol.9 (2), p.e001701

2021

Volltextzugriff (PDF)

Mucosal Melanoma of the Head and Neck: A Retrospective Review and Current Opinion

Frontiers in surgery, 2021-01, Vol.7, p.616174-616174

2021

Volltextzugriff (PDF)

Modeling tumor size dynamics based on real‐world electronic health records and image data in advanced melanoma patients receiving immunotherapy

CPT: pharmacometrics and systems pharmacology, 2023-08, Vol.12 (8), p.1170-1181

2023

Volltextzugriff (PDF)

Cancer Care of Children, Adolescents and Adults With Autism Spectrum Disorders: Key Information and Strategies for Oncology Teams

Frontiers in oncology, 2021-01, Vol.10, p.595734-595734

2021

Volltextzugriff (PDF)

Testing a Model of Care for Patients on Immune Checkpoint Inhibitors Based on Electronic Patient-Reported Outcomes: Protocol for a Randomized Phase II Controlled Trial

JMIR research protocols, 2023-10, Vol.12, p.e48386-e48386

2023

Volltextzugriff (PDF)

68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis

Journal for immunotherapy of cancer, 2021-10, Vol.9 (10)

2021

Volltextzugriff (PDF)

Personalized treatment of immune checkpoint inhibitor-related severe hemophagocytic lymphohistiocytosis (HLH)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e15079-e15079

2020

Volltextzugriff (PDF)

Targeting immune checkpoints in breast cancer: an update of early results

ESMO open, 2017, Vol.2 (5), p.e000255-e000255, Article e000255

2017

Volltextzugriff (PDF)

Deep mapping of the cytokine release syndrome inflammatory continuum: Comprehensive grade-specific profiling and differentiation from sepsis in patients receiving immune checkpoint therapy

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.12129-12129

2024

Volltextzugriff (PDF)

Melanoma neoantigen vaccines: Are we getting more personal now?

Med (New York, N.Y. : Online), 2024-04, Vol.5 (4), p.288-290

2024

Volltextzugriff (PDF)

Physical approaches to treat glioblastoma

Current opinion in oncology, 2020-11, Vol.32 (6), p.640-649

2020

Volltextzugriff (PDF)

Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series

Journal of neurology, 2024-04, Vol.271 (4), p.1947-1958

2024

Volltextzugriff (PDF)

Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors

Supportive care in cancer, 2023-08, Vol.31 (8), p.484-484, Article 484

2023

Volltextzugriff (PDF)

2022-RA-1353-ESGO Severe anaemia following frontline maintenance with iPARP in a BRCA1 mutated high-grade serous ovarian cancer: an unexpected foe

International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A400-A400

2022

Volltextzugriff (PDF)

2022-RA-1349-ESGO Treated as a skin carcinoma: recurrent, metastatic squamous cell carcinoma from a degenerated mature teratoma of the ovary

International journal of gynecological cancer, 2022-10, Vol.32 (Suppl 2), p.A327-A328

2022

Volltextzugriff (PDF)

Endometrial cancer in the crossroads of modernity and immunotherapy

Revue médicale suisse, 2023-05, Vol.19 (827), p.944

2023

Volltextzugriff (PDF)

Immunothérapie dans le cancer de la vessie : mise à jour 2021

Revue médicale suisse, 2021, Vol.17 (739), p.974-977

2021

Volltextzugriff (PDF)

Cancer de l’endomètre : entre modernité et immunothérapie

Revue médicale suisse, 2023, Vol.19 (827), p.944-949

2023

Volltextzugriff (PDF)

Chimeric antigen receptor T ‐cells safety: A pharmacovigilance and meta‐analysis study

American journal of hematology, 2021-09, Vol.96 (9), p.1101-1111

2021

Volltextzugriff (PDF)

Long-lasting, irreversible and late-onset immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs): A real-world data analysis

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e15095-e15095

2020

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(39)

Sprache

Englisch
(34)
Französisch
(5)

Erscheinungsjahr

n.n

Thema

Humans
(15)
Science & Technology
(15)
Life Sciences & Biomedicine
(14)
Cancer
(10)
Oncology
(10)
Immunotherapy
(9)
Melanoma
(8)
Patients
(8)
Life Sciences
(4)
Male
(4)
Medical Oncology
(4)
Quality Of Life
(4)
Antineoplastic Agents, Immunological - Adverse Effects
(3)
Cancer Therapies
(3)
Female
(3)
Immunology
(3)
Metastasis
(3)
Mutation
(3)
Retrospective Studies
(3)
Aged
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma

Interactive process mining of cancer treatment sequences with melanoma real-world data

Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

Mucosal Melanoma of the Head and Neck: A Retrospective Review and Current Opinion

Modeling tumor size dynamics based on real‐world electronic health records and image data in advanced melanoma patients receiving immunotherapy

Cancer Care of Children, Adolescents and Adults With Autism Spectrum Disorders: Key Information and Strategies for Oncology Teams

Testing a Model of Care for Patients on Immune Checkpoint Inhibitors Based on Electronic Patient-Reported Outcomes: Protocol for a Randomized Phase II Controlled Trial

68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis

Personalized treatment of immune checkpoint inhibitor-related severe hemophagocytic lymphohistiocytosis (HLH)

Targeting immune checkpoints in breast cancer: an update of early results

Deep mapping of the cytokine release syndrome inflammatory continuum: Comprehensive grade-specific profiling and differentiation from sepsis in patients receiving immune checkpoint therapy

Melanoma neoantigen vaccines: Are we getting more personal now?

Physical approaches to treat glioblastoma

Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series

Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors

Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma

2022-RA-1353-ESGO Severe anaemia following frontline maintenance with iPARP in a BRCA1 mutated high-grade serous ovarian cancer: an unexpected foe

2022-RA-1349-ESGO Treated as a skin carcinoma: recurrent, metastatic squamous cell carcinoma from a degenerated mature teratoma of the ovary

Endometrial cancer in the crossroads of modernity and immunotherapy

Immunothérapie dans le cancer de la vessie : mise à jour 2021

Cancer de l’endomètre : entre modernité et immunothérapie

Chimeric antigen receptor T ‐cells safety: A pharmacovigilance and meta‐analysis study

Long-lasting, irreversible and late-onset immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs): A real-world data analysis

Suchergebnisse filtern